RETA-GLP3 15MG & AOD 9604 10MG BUNDLE (ENGLISH)
HIGH QUALITY PEPTIDE
$250.00$225.00
Reta-GLP3 (Development Code: LY3437943) is a once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It belongs to the incretin mimetic class alongside semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®), but goes a step further by targeting a third receptor.
The term "triple agonist" refers to its mechanism of action. Retatrutide activates three receptors simultaneously. Semaglutide targets one receptor (GLP-1). Tirzepatide targets two receptors (GLP-1 + GIP). Retatrutide targets all three: GLP-1 + GIP + glucagon. Each additional receptor has been associated with significantly greater weight loss in clinical trials, and this trend has continued with retatrutide.
AOD-9604 is one of the most extensively studied peptides in the field of fat loss and metabolic health—and for good reason. Derived directly from human growth hormone (HGH), it was specifically designed to retain the fat-burning properties of HGH while avoiding the unwanted side effects commonly associated with long-term growth hormone therapy.